CPC Scientific
Private Company
Funding information not available
Overview
CPC Scientific is an established, privately-held peptide and oligonucleotide CDMO with over 25 years of global operations, serving top pharma and biotech companies in more than 50 countries. It has evolved from a research-focused service provider into a full-scale CDMO with significant GMP manufacturing capacity, supporting over 300 CMC development projects and 13 commercial GMP programs. The company's integrated platform for peptides, oligos, and their conjugates positions it in the high-growth TIDES (Therapeutic Oligonucleotides and Peptides) market, leveraging process innovations for sustainable, large-scale production.
Technology Platform
Integrated CDMO platform for peptide synthesis (SPPS), oligonucleotide synthesis, and peptide-oligonucleotide conjugate (POC) manufacturing, with capabilities spanning research-grade to commercial GMP production.
Opportunities
Risk Factors
Competitive Landscape
CPC Scientific competes in the peptide and oligonucleotide CDMO space against large, diversified CDMOs (e.g., Lonza, Catalent), established pure-play peptide CDMOs (e.g., Bachem, PolyPeptide Group), and a growing number of specialized oligonucleotide manufacturers. Its integrated conjugate platform and focus on late-phase/commercial scale are key differentiators.